Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

MiMedX Tumbles as Two Late-Stage Trials Disappoint

Stock MarketsSep 13, 2021 07:57AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

By Dhirendra Tripathi

Investing.com – MiMedx stock (NASDAQ:MDXG) plunged by more than 52% in Monday’s premarket after the scandal-plagued company suffered setbacks in two late-stage musculoskeletal clinical trials.

The company said in a regulatory release that its key product - the dehydrated Human Amnion Chorion Membrane (mdHACM) - failed to meet critical endpoints in two separate clinical trials: a Phase 2B trial for the treatment of Knee Osteoarthritis (KOA) and a Phase 3 clinical trial for the treatment of Plantar Fasciitis (PF).

The findings do not support an application for a biologics license in the latter case, it added. The company said it will still pursue phase-III KOA confirmatory studies.

The results are a body blow for a company that has been overshadowed by the past wrongdoings of its previous management. Former chief executive Parker Petit and chief operating officer William Taylor was sentenced to a year in jail in Februaryy after being found guilty of inflating the company's financial statements in the middle of the last decade. The fraud had come to light in the course of a bitter public fight between Parker and short-sellers led by Mark Cohodes.

MiMedX's product pipeline had enough support on Wall Street and in financial media such as Bloomberg Opinion to fuel a 65% rally this year.

"If the $MDXG products do not work, as evidenced by the two failed clinical trials announced this morning, then the years of arguing are done, right?" tweeted Stat News's Adam Feuerstein.

MiMedX Tumbles as Two Late-Stage Trials Disappoint
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email